Access to Treatment of Hepatitis C in Prison Inmates

  • Paul Strock
  • Joël Mossong
  • Karine Hawotte
  • Vic Arendt
Original Article

DOI: 10.1007/s10620-008-0483-8

Cite this article as:
Strock, P., Mossong, J., Hawotte, K. et al. Dig Dis Sci (2009) 54: 1325. doi:10.1007/s10620-008-0483-8


We conducted a prospective study to investigate access to treatment in hepatitis C in 268 prisoners. Hepatitis C positivity had been known for 182 prisoners previously and 19 reported previous attempts to treat (10%). In comparison, during our study, 86/268 prisoners (32%) started therapy (P < 0.0001). They represented 41% of 211 prisoners with a positive viral load. In the genotype 2 or 3 group, 46 prisoners (50%) started therapy versus 40 prisoners (33%) with other genotypes (P = 0.01). This difference was due to prisoners waiting for liver biopsy. On an intention to treat basis, 45 prisoners (52%) achieved sustained virological response 6 months after the end of therapy. We conclude that a stay in prison is an effective opportunity to treat a group of hepatitis C patients which otherwise have very limited access to therapy.


Hepatitis C Prison Therapy Epidemiology 

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Paul Strock
    • 1
  • Joël Mossong
    • 2
  • Karine Hawotte
    • 3
  • Vic Arendt
    • 4
  1. 1.Hepatogastroenterology, Service d’Hépato-GastroentérologieCentre Hospitalier de LuxembourgLuxembourg-CityLuxembourg
  2. 2.MicrobiologyLaboratoire National de SantéLuxembourg-CityLuxembourg
  3. 3.Retrovirology LaboratoryCentre Hospitalier de LuxembourgLuxembourg-CityLuxembourg
  4. 4.Infectious DiseasesCentre Hospitalier de LuxembourgLuxembourg-CityLuxembourg

Personalised recommendations